

Letter to the Editor

Dipyridamole stress echocardiography for the diagnosis of cardiac allograft vasculopathy in heart transplant recipients

Dear Editor,

We read with great interest the article titled "Cardiac allograft vasculopathy after heart transplantation: current prevention and treatment strategies" by Spartalis et al¹. Cardiac allograft vasculopathy (CAV) affects over 50% of recipients within 10 years of transplant and represents an important cause of morbidity and mortality post-transplantation². Early detection of CAV is critical because it allows the identification of high-risk patients and the implementation of therapeutic strategies before end-stage heart failure³. Current guidelines recommend coronary angiography to monitor the development and progression of CAV⁴.

Dobutamine stress echocardiography (DSE) has been reported to be the main non-invasive tool for the diagnosis of CAV, with a high negative predictive value (89%)^{5,6}. Coronary microvascular dysfunction defined by means of a reduced coronary flow reserve (CFR), is emerging as a strong predictor of outcome in heart transplantation⁷. In this regard, Sade et al⁸ reported that the assessment of CFR together with dobutamine stress echocardiography improved the sensibility and diagnostic accuracy of the latter method. Dipyridamole stress echocardiography (DiSE) in detecting CAV was first proposed by Picano et al⁹. They showed that in transplant recipients, the best marker of acute cardiac rejection was DiSE-induced ST segment depression without detectable impairment in regional systolic function. We assessed the diagnostic value of the evaluation of both wall motion and CFR during high-dose DiSE for the diagnosis of CAV in 74 heart transplant patients. Our results show that a normal DiSE result combined with the evaluation of wall motion abnormalities and CFR analysis is highly predictive of the absence of significant CAV (negative predictive value: 91%), which is similar to studies examining dobutamine stress echocardiography. Dual DiSE could be helpful in selected patients to adjust the time and indications of coronary angiography. Longer series are needed to validate this proposal.

Conflict of interest

The authors declare no conflicts of interest.

References

- 1) SPARTALIS M, SPARTALIS E, TZATZAKI E, TSILIMIGRAS DI, MORIS D, KONTOGIANNIS C, ILIOPOULOS DC, VOUDRIS V, SIASOS G. Cardiac allograft vasculopathy after heart transplantation: current prevention and treatment strategies. *Eur Rev Med Pharmacol Sci* 2019; 23: 303-311.
- 2) KHUSH KK, CHERIKH WS, CHAMBERS DC, GOLDFARB S, HAYES D, KUCHERYAVAYA AY, LEVVEY BJ, MEISER B, ROSSANO JW, STEHLIK J. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report–2018; Focus theme: multiorgan transplantation. *J Heart Lung Transplant* 2018; 37: 1155-1168.
- 3) ANDREASSEN AK, ANDERSSON B, GUSTAFSSON F, EISKJAER H, RADEGRAN G, GUDE E, JANSSON K, SOLBU D, KARASON K, ARORA S, DELLGREN G, GULLESTAD L. Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE Study. *Am J Transplant* 2016; 16: 1238-1247.

- 4) COSTANZO MR, DIPCHAND A, STARLING R, ANDERSON A, CHAN M DESAI S, FEDSON S, FISHER P, GONZALES-STAWINSKI, G, MARTINELLI L, MCGIFFIN D, SMITH J, TAYLOR D, MEISER B, WEBBER S, BARAN D, CARBONI M, DENGLER T, FELDMAN D, FRIGERIO M, KFOURY A, KIM D, KOBASHIGAWA, J, SHULLO M, STEHLIK J, TEUTEBERG J, UBER P, ZUCKERMANN A, HUNT S, BURCH M, BHAT G, CANTER C, CHINNOCK R, CRESPO-LEIRO M, DELGADO R, DOBBELS F, GRADY K, KAO W, LAMOUR J, PARRY G, PATEL J, PINI D, TOWBIN J, WOLFEL G, DELGADO D, EISEN H, GOLDBERG L, HOSENPUJ J, JOHNSON M, KEOGH A, LEWIS C, O'CONNELL J, ROGERS J, ROSS H, RUSSELL S, VANHAECKE J. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. *J Heart Lung Transplant* 2010; 29: 914-956.
- 5) SPES CH, MUDRA H, SCHNAACK SD, KLAUSS V, REICHLER FM, UBERFUHR P, THEISEN K, ANGERMANN CE. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. *Am J Cardiol* 1996; 78: 168-174.
- 6) CHIRAKARNJANAKORN S, STARLING RC, POPOVIĆ ZB, GRIFFIN BP, DESAI MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: Diagnostic accuracy and predictors of outcomes. *J Heart Lung Transplant* 2015; 34: 710-717.
- 7) TONA F, OSTO E, FAMOSO G, PREVIATO M, FEDRIGO M, VECCHIATI A, PERAZZOLO MARRA M, TELLATIN S, BELLU R, TARANTINI G, FELTRIN G, ANGELINI A, THIENE G, GEROSA G, ILICETO S. Coronary microvascular dysfunction correlates with the new onset of cardiac allograft vasculopathy in heart transplant patients with normal coronary angiography. *Am J Transplant* 2015; 15: 1400-1406.
- 8) SADE LE, EROĞLU S, YÜCE D, BIRCAN A, PIRAT B, SEZGIN A, AYDINALP A, MÜDERRISOĞLU H. Follow-up of heart transplant recipients with serial echocardiographic coronary flow reserve and dobutamine stress echocardiography to detect cardiac allograft vasculopathy. *J Am Soc Echocardiogr* 2014; 27: 531-539.
- 9) PICANO E, DE PIERI G, SALERNO JA, ARBUSTINI E, DISTANTE A, MARTINELLI L, PUCCI A, MONTEMARTINI C, VIGANO M, DONATO L. Electrocardiographic changes suggestive of myocardial ischemia elicited by dipyridamole infusion in acute rejection early after heart transplantation. *Circulation* 1990; 81: 72-77.

I. Álvarez Pichel¹, O.C. Fernández Cimadevilla², J.M. De la Hera Galarza³, M. Martín Fernández³

¹ Servicio de Cardiología, Hospital Vital Álvarez Buylla, Oviedo, Spain

² Servicio de Cardiología, Hospital San Agustín, Spain, Avilés

³ Área del Corazón, Hospital Universitario Central de Asturias, Oviedo, Spain